All News

Program Leads Patients With Cancer on ‘The Right Track’

September 24th 2020, 9:00pm

Article

Finding the best care team can make all the difference for patients with diseases like multiple myeloma.

Clinical Trials are Fueling Medical Breakthroughs in Cancer

September 24th 2020, 6:00pm

Article

Clinical trials lead to new cancer treatments — and can give a patient access to effective drugs years before they’re made available to the public.

The ABC’s of Pediatric Cancer

September 24th 2020, 3:00pm

Podcast

In this week’s episode of the CURE® Talks Cancer podcast, we chat with Dr. Tanja Gruber, the chief of pediatric hematology, oncology and stem cell transplantation at Stanford Children’s Health, about how pediatric cancer treatment is evolving thanks to advances in treatments like immunotherapy, and what parents should do after their child receives a diagnosis.

CURE’s Clinical Trial Corner: September 2020

September 24th 2020, 1:00pm

Article

Here is a list of some recent trials that launched within the cancer space in September.

Experimental Treatment Shows Promise for Certain Cases of Advanced NSCLC

September 23rd 2020, 9:00pm

Article

There is no approved treatment that targets the KRAS p.G12C mutation that drives some cancers like non-small cell lung cancer. But a recent study shows how the experimental drug sotorasib sparked responses in some patients with advanced non-small cell lung cancer that harbored the mutation.

Coming of Age: New Research Efforts are Improving Treatment of Childhood Blood Cancers

September 23rd 2020, 6:00pm

Article

For years, childhood blood cancers were understudied forcing patients’ treatments into a one size-fits-all approach. But new efforts are changing that.

The Price of Hope: Weighing the Cost of CAR-T Cell Therapy in Treating Blood Cancers

September 23rd 2020, 3:00pm

Article

Weighing the cost of CAR-T cell therapy in treating blood cancers is a finical burden for many patients with blood cancer.

Lynparza Significantly Improves Survival in Subset of Patients with Metastatic Prostate Cancer

September 23rd 2020, 1:00pm

Article

The PARP inhibitor Lynparza reduced the risk for death by 31% in men with metastatic castration-resistant prostate cancer compared with Xtandi or Zytiga plus the corticosteroid prednisone.

Tecentriq Combo Improves Response Rates in Early TNBC, Regardless of PD-L1 Status

September 22nd 2020, 9:00pm

Article

Findings from a randomized phase 3 study showed that adding neoadjuvant Tecentriq to a chemotherapy regimen of Abraxane, Adriamycin and Cytoxan in patients with stage 2 or 3 triple-negative breast cancer significantly improved pathologic complete responses, compared with placebo plus chemotherapy.

Advances in the Treatment of Mantle Cell Lymphoma are Greatly Improving the Long-Term Outlook for Patients

September 22nd 2020, 6:00pm

Article

Exciting advances in treatment options for patients with mantle cell lymphoma are greatly improving the outlook for long-term remissions.